COVID-19
The Lancet: Russian Coronavirus Sputnik V Vaccine Achieves Over 90% Efficacy
Clinical News
Febbraio 3, 2021
The Lancet: Russian Coronavirus Sputnik V Vaccine Achieves Over 90% Efficacy
Russia’s Sputnik V vaccine was 91.6% effective in preventing people from developing Covid-19, according to peer-reviewed results from its late-stage clinical trial published yesterday in The Lancet international medical journal.…
TIF Updated Vaccinations & Therapeutic Drugs COVID-19 Guide Has Landed
NOVITÀ
Gennaio 29, 2021
TIF Updated Vaccinations & Therapeutic Drugs COVID-19 Guide Has Landed
A comprehensive Guide for both existing and developing vaccines and treatments against COVID-19, exclusively developed by TIF for its global thalassaemia community. Featuring: Pfizer, Moderna, AstraZeneca: What are the differencies…
Blood Supply Challenges & Transfusion Care of Patients With Haemoglobinopathies During COVID-19 Pandemic
NOVITÀ
Gennaio 22, 2021
Blood Supply Challenges & Transfusion Care of Patients With Haemoglobinopathies During COVID-19 Pandemic
The COVID-19 pandemic has had an impact on blood supply in several countries, jeopardizing the already demanding and often suboptimal care for haemoglobinopathies patients, mainly in developing and low-income countries…
Just Updated: TIF’s Vaccinations & Therapeutic Drugs for COVID-19 Guide
NOVITÀ
Gennaio 7, 2021
Just Updated: TIF’s Vaccinations & Therapeutic Drugs for COVID-19 Guide
Everything you need to know about the different COVID-19 vaccines, both already available and developing, in one place! Discover our newly updated Guide ”Vaccinations & Therapeutic Drugs for COVID-19”, containing…
COVID-19 Vaccines and Haemoglobin Disorders: The Latest Position Statement of the Thalassaemia International Federation
NOVITÀ
Dicembre 22, 2020
COVID-19 Vaccines and Haemoglobin Disorders: The Latest Position Statement of the Thalassaemia International Federation
In view of the plans made by national health authorities in every country across the world for the widespread vaccination of individuals against the SARS-CoV-2 virus, the Thalassaemia International Federation…
Joint ETA, TIF & ESHR Conference On Thalassaemia To Take Place On 25-26 November 2020 in Cairo
Member News
Novembre 23, 2020
Joint ETA, TIF & ESHR Conference On Thalassaemia To Take Place On 25-26 November 2020 in Cairo
A Joint Conference on thalassaemia by the Egyptian Thalassemia Association (ETA), the Egyptian Society of Hematology & Research (ESHR) and the Thalassaemia International Federation (TIF) will be held on 25-26…
Leave No Patient Behind: A TIF Declaration For Access To Health At The Time of The COVID-19 Pandemic
NOVITÀ
Novembre 10, 2020
Leave No Patient Behind: A TIF Declaration For Access To Health At The Time of The COVID-19 Pandemic
Download the TIF Declaration HERE
Pfizer’s COVID-19 Vaccine Candidate Shown To Be 90% Effective, Early Findings Suggest
NOVITÀ
Novembre 10, 2020
Pfizer’s COVID-19 Vaccine Candidate Shown To Be 90% Effective, Early Findings Suggest
The drug maker Pfizer announced yesterday that an early analysis of its coronavirus vaccine trial suggested the vaccine was robustly effective in preventing Covid-19, a promising development as the world…
Roche and Atea Pharmaceuticals Link Up To Co-Develop Remdesivir Rival Drug For COVID-19
Clinical News
Ottobre 26, 2020
Roche and Atea Pharmaceuticals Link Up To Co-Develop Remdesivir Rival Drug For COVID-19
The two companies will jointly develop, manufacture and distribute AT-527, Atea’s investigational oral antiviral for the potential treatment of COVID-19. According to Roche, AT-527 blocks the viral RNA polymerase enzyme…
Johnson & Johnson Pauses Clinical Trials For Its Covid-19 Vaccine Over Participant’s Illness
Clinical News
Ottobre 13, 2020
Johnson & Johnson Pauses Clinical Trials For Its Covid-19 Vaccine Over Participant’s Illness
Johnson & Johnson has paused its Covid-19 vaccine trial due to an “unexplained illness” in a participant, the company confirmed yesterday evening. The pharmaceutical giant was unclear if the patient…